Member Info for Bella6532

Posted this morning by Richob
'Eliot Forster at this one:
https://sachsevent.com/afterevent/7th-ioif/speakers

Forster is representing his othee company, not Avacta.
If you check the Pharma speakers profiles they give you a good idea of the sort of deals they do and if you research said deal announcements you get a feel for the stage at which said deals are done.
Personally I don't think T/O is on the cards...I do think, however, we could see a relatively quick licence deals against good AVA6000 results. Good results will be the key that 'unlocks' this potential ans we have been told this.

Retireby40...'Once below 4% they have to let DVRG know to issue and RNS and then again once below 3%.'
Yes and no...if they put in a sell order to get rid of all their shares with a broker and that order is transacted over a period of time then once thevorder is completed they don't have to report. In fact many companies go below the 3% threshold and don't report. It can be a bit 'loose' in the area of reporting on AIM...

Toatie...When I talk to chaps who have retired they all say the same...they get the daily 'honey do list' and it never seems to end...careful for what you wish for hun...lol.

Hurst10...the money follows interest rates...the Fed's hiking interest rates to bring in overseas money to the US to try and make the economy look good going into the Mid Terms...if they're not careful they could generate the next housing crash over there.

Nanomat...and I would add to that the fact it is unblinded. This allows everyone concerned to see the data and to make 'informed' decisions regarding patient care/safety.

As has been mentioned, dox is a nasty drug and if cancer cells develop a tollerance/resistance to current max dosage then higher doses in the form of AVA6000 without side effects might just be what is needed to overcome the tollerance/resistance. I do hope for some (if not all) the word terminal ceases to exist for them.

Donkeyeeyore...mid price trades but we do seem to get a lot of them coinciding with the green box brigade and when the SP is down...seen it several times on here and we usually end up with some large after hours going through. All done to confuse the algorithms to keep SP steady to help benefit an order being worked through. Yes there is a certain amount of manipulation but not in a bad or illegal way...just done to keep the algorithms from kicking in especially when there's a share shortage.

Nanomat...and when they say they are leaving, had enough, they've sold up etc it's also a good sign their job is done and the SP is due a little bounce. The green boxes dusappear and so do all those annoying 'unknown' trades...and sanity returns.

David Wilson...Experience
Avacta Graphic
Commercial Director, Diagnostics
Avacta
Aug 2019 - Present3 years 3 months

Wetherby, Yorkshire. United Kingdom

Avacta Diagnostics, part of LSE AIM-listed Avacta Group plc (LSE:AVCT), aims to become the leading provider of innovative, next generation diagnostic solutions by utilising its proprietary Affimer® platform to develop AffiDX® immunodiagnostic (IVD) tests, starting with the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test. We have also established commercial relationships with IVD companies worldwide to improve the clinical utility of diagnostic testing solutions, by combining bespoke Affimer® reagents with leading diagnostic platform technologies

Chair, Near Patient Testing Working Party, British In Vitro Diagnostics Association (BIVDA)

Show less
Linear Diagnostics Limited Graphic
Non-Executive Director
Linear Diagnostics Limited
Nov 2017 - Present5 years

Birmingham, United Kingdom

University of Birmingham spin-out developing rapid, accurate point of care diagnostic device to rapidly detect pathogens in primary care settings.

David Wilson is also Exec Dir of Linear Diagnotics...scroll down the page in this link.
https://www.lineardiagnostics.com/company/

If you click on products the only thing they list is Diagnotic Rapid Test.

https://www.medica-tradefair.com/vis/v1/en/exhibitors/medcom2022.2727408?oid=80396&lang=2&_query=Avacta&f_type=profile

'Welcome to RAPIvD. A world-class contract research company operating at the cutting edge of rapid in vitro diagnostics and particularly, lateral flow technology.

?

Imagine a device that works in a similar way to a pregnancy or covid test. A small, convenient, easy-to-use device that can detect an illness or condition in a matter of minutes. Well, that’s what we develop at RAPIvD – and we’re working with companies and institutions around the world to make these devices a vital part of future medical and personal healthcare practices.'

Both Avacta and Raplvd are exhibiting 14 - 17 November...watch this space!!

https://www.medica-tradefair.com/kati-cgi/kati/vis/custom/ext2/download.cgi?ticket=g_u_e_s_t&lang=2&fair=medcom2022&dl=html

Oakhust...'It takes 2 weeks max for a biopsy report, am speculating they may well have tested bowl tumour cells post Ava6000 , it’s quite simple to obtain with no discomfort of note for patient.'
It's most likely all these patients underwent a biopsy procedure which gave them their cancer diagnosis in the first place and if they didn't undergo a stoma operation there is a good chance they would agree to the scope biopsy via the rectum or stoma.

'The ALS-6000-101 protocol has been designed as a data-rich clinical study that will provide the Company with detailed insights into the safety and pharmacokinetics of AVA6000. The presence of Doxorubicin in the tumour tissue is also a key indicator that the proposed mechanism of FAPa-activated release of Doxorubicin is working. This information can only be obtained from tumour biopsies, which are not mandatory in the Phase I study, but the Company remains confident of gathering some biopsy data from the Phase Ia dose escalation study. The Company has worked with partners at a UK based, world-leading pathology laboratory to put in place the validated assays to analyse biopsy samples.'

Mr A you might wish to read the RNS again. It is key according to Avacta...

Did they buy them to show they were serious/commited to tge company...get access to meeting etc...

'The AffiDX ® SARS-CoV-2 antigen lateral flow test, which combined the use of an antibody and an Affimer ® reagent in the test strip, had excellent performance in terms of sensitivity and specificity with the emerging variants of the virus until the Omicron variant appeared in late 2021. The AffiDX ® SARS CoV-2 antigen lateral flow test contained both a proprietary Affimer ® reagent and a commercially available antibody. Our data showed that the Affimer ® reagent in the AffiDX ® test continued to detect the Omicron variant with the same sensitivity as the Delta variant, but the antibody, with which the Affimer ® is paired, had been affected by the additional Omicron mutations.



Early in 2022, the Company independently took the decision to pause sales of the AffiDX ® antigen test whilst it replaces the antibody in the product to ensure that its performance with the Omicron variant matches the high performance with previous mutations.



This re-development is ongoing, and the Company will update the market as soon as it is able to provide a reliable timeline to product re-launch.



The Diagnostics Division is now focused on developing a broader pipeline of new IVD products outside of COVID-19 to drive future revenues and the profitability of the Division. This pipeline is designed to deliver, over the longer term, a full portfolio of IVD products with a focus on decentralised testing for professionals and consumers. The Company is addressing four key areas of respiratory, infectious and cardiovascular disease, cancer and general health and well-being (e.g. hormones, vitamins). The Company is exploring multiple pathways to develop this portfolio of IVD products and revenue as rapidly as possible.'

The cash is not an issue...licencing deal(s) with upfront payments will take care of that plus new covid test...yes still ongoing and again with no outside partners ???!!! Going it alone or licence deal...

Timescales....
'Post-period end, in August 2022, the third cohort was completed and the SDMC approved dose escalation to 200mg/m2 in the fourth cohort which is now recruiting patients in the UK. The fourth cohort is expected to be completed during Q4 2022.
The ALS-6000-101 protocol has been designed as a data-rich clinical study that will provide the Company with detailed insights into the safety and pharmacokinetics of AVA6000. The presence of Doxorubicin in the tumour tissue is also a key indicator that the proposed mechanism of FAPa-activated release of Doxorubicin is working. This information can only be obtained from tumour biopsies, which are not mandatory in the Phase I study, but the Company remains confident of gathering some biopsy data from the Phase Ia dose escalation study. The Company has worked with partners at a UK based, world-leading pathology laboratory to put in place the validated assays'

If resukts are good tgen who knows what other collaboration/licencing agreement are/could be in the pipeline.
We are only at the very start...